A clinical investigation involving 24 breast cancer patients administered CLA orally at 7.5 g/day for 20 days revealed inhibition in the expression of fatty acid synthase (FASN) and lipoprotein lipase (LPL), indicating breast tumor growth suppression. This evidence concerns the gene FASN and breast carcinoma.